Published in Free Radic Res on February 01, 2009
Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis (2010) 1.54
Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J (2009) 1.47
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol (2012) 1.32
Lipoic acid: energy metabolism and redox regulation of transcription and cell signaling. J Clin Biochem Nutr (2010) 1.20
Mitochondrial permeability transition pore in Alzheimer's disease: cyclophilin D and amyloid beta. Biochim Biophys Acta (2009) 1.19
p53, oxidative stress, and aging. Antioxid Redox Signal (2011) 1.18
Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol (2010) 1.18
Mitochondrial permeability transition pore is a potential drug target for neurodegeneration. Biochim Biophys Acta (2013) 1.05
Synaptic mitochondrial pathology in Alzheimer's disease. Antioxid Redox Signal (2011) 1.04
Antioxidant therapies for Alzheimer's disease. Oxid Med Cell Longev (2012) 1.03
Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Am J Med Genet A (2011) 1.02
Association among amyloid plaque, lipid, and creatine in hippocampus of TgCRND8 mouse model for Alzheimer disease. J Biol Chem (2010) 0.98
Oxidative Stress in Neurodegenerative Diseases. Mol Neurobiol (2015) 0.89
Novel therapeutics for Alzheimer's disease: an update. Curr Opin Drug Discov Devel (2010) 0.84
Frontiers in Alzheimer's disease therapeutics. Ther Adv Chronic Dis (2011) 0.84
Neuronal failure in Alzheimer's disease: a view through the oxidative stress looking-glass. Neurosci Bull (2014) 0.81
Short-term supplementation with acetyl-L-carnitine and lipoic acid alters plasma protein carbonyl levels but does not improve cognition in aged beagles. Exp Gerontol (2009) 0.81
Early onset Alzheimer's disease and oxidative stress. Oxid Med Cell Longev (2014) 0.79
The Effect of Lipoic Acid Therapy on Cognitive Functioning in Patients with Alzheimer's Disease. J Neurodegener Dis (2013) 0.79
Emilia coccinae (SIMS) G Extract improves memory impairment, cholinergic dysfunction, and oxidative stress damage in scopolamine-treated rats. BMC Complement Altern Med (2015) 0.79
Oxidative Stress in Alzheimer's Disease: Should We Keep Trying Antioxidant Therapies? Cell Mol Neurobiol (2015) 0.77
An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels. Am J Transl Res (2016) 0.76
Mitochondrial Drugs for Alzheimer Disease. Pharmaceuticals (Basel) (2009) 0.76
Mechanisms of divalent metal toxicity in affective disorders. Toxicology (2015) 0.76
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA (2007) 11.87
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med (1997) 7.56
Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol (2001) 4.80
Mitochondrial abnormalities in Alzheimer's disease. J Neurosci (2001) 4.39
A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology (2005) 3.78
Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med (1997) 3.74
Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiol Aging (2001) 3.48
Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A (1997) 3.47
Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci (1997) 3.08
Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci (1997) 2.91
RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci (1999) 2.86
4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem (1997) 2.80
Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med (2008) 2.74
Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging (2000) 2.40
Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. Am J Pathol (2008) 2.09
Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol Behav (2002) 1.99
Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol (2006) 1.92
Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A (1994) 1.91
Alzheimer's disease: the two-hit hypothesis. Lancet Neurol (2004) 1.81
Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet (1999) 1.74
Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol (1999) 1.69
Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem (1998) 1.68
The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem (2003) 1.67
Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem (2005) 1.64
Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol (1994) 1.62
Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem (2005) 1.61
In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem (2000) 1.60
Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nutr Neurosci (2003) 1.50
Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport (1999) 1.49
Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann N Y Acad Sci (2004) 1.49
Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J (2003) 1.47
Heme oxygenase-1: molecular mechanisms of gene expression in oxygen-related stress. Antioxid Redox Signal (2002) 1.40
Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol (2006) 1.33
Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. J Neurosci (2007) 1.28
Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging (2006) 1.28
Chronic systemic D-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: protective effects of R-alpha-lipoic acid. J Neurosci Res (2006) 1.26
Alzheimer Disease and Oxidative Stress. J Biomed Biotechnol (2002) 1.26
Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. Biochim Biophys Acta (2006) 1.26
Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch Neurol (1993) 1.22
Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Med (2008) 1.22
Alpha-lipoic acid and cardiovascular disease. J Nutr (2003) 1.22
Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J Alzheimers Dis (2007) 1.19
Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med (2002) 1.17
In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J Neurochem (2000) 1.16
Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic Biol Med (2001) 1.14
Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease. Neurobiol Dis (2004) 1.13
Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease. J Alzheimers Dis (1998) 1.11
Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease. Free Radic Biol Med (2007) 1.11
Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis. J Neural Transm Suppl (2007) 1.11
Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch Neurol (2007) 1.10
Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol (2004) 1.09
Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J Biol Chem (1999) 1.07
Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc (2002) 1.06
Oxidative imbalance in Alzheimer's disease. Mol Neurobiol (2005) 1.05
Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther (2006) 1.01
Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. Biochemistry (2007) 1.01
Amyloid-beta junkies. Lancet (2000) 1.00
Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. Free Radic Biol Med (2006) 0.98
Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic Biol Med (2005) 0.98
Increases in luteinizing hormone are associated with declines in cognitive performance. Mol Cell Endocrinol (2007) 0.96
Is antioxidant therapy a viable alternative for mild cognitive impairment? Examination of the evidence. Dement Geriatr Cogn Disord (2007) 0.96
Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res (2003) 0.95
Neuritic plaques and vessels of visual cortex in aging and Alzheimer's dementia. Neurobiol Aging (1990) 0.94
Effects of alpha-tocopherol on an animal model of tauopathies. Free Radic Biol Med (2004) 0.94
Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide. Free Radic Biol Med (2007) 0.94
Cell death after exposure to subarachnoid hemolysate correlates inversely with expression of CuZn-superoxide dismutase. Stroke (2000) 0.93
Lack of correlation between plaque burden and cognition in the aged monkey. Acta Neuropathol (1997) 0.93
Current status of antioxidant therapy for Alzheimer's Disease. J Am Geriatr Soc (1998) 0.92
Predicting the failure of amyloid-beta vaccine. Lancet (2002) 0.91
Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways. Antioxid Redox Signal (2003) 0.89
Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau. Am J Alzheimers Dis Other Demen (2006) 0.89
The state versus amyloid-beta: the trial of the most wanted criminal in Alzheimer disease. Peptides (2002) 0.89
Reduction of inclusion body pathology in ApoE-deficient mice fed a combination of antioxidants. Free Radic Biol Med (2003) 0.89
Hallmarks of protein oxidative damage in neurodegenerative diseases: focus on Alzheimer's disease. Amino Acids (2007) 0.87
Laminar distribution of neuritic plaques in normal aging, Alzheimer's disease and Down's syndrome. Acta Neuropathol (1988) 0.87
Age-related changes in the brain of the dog. Vet Pathol (1999) 0.86
Alpha-lipoic acid supplementation prevents symptoms of vitamin E deficiency. Biochem Biophys Res Commun (1994) 0.84
Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer's disease. J Alzheimers Dis (1999) 0.82
Will preventing protein aggregates live up to its promise as prophylaxis against neurodegenerative diseases? Brain Pathol (2003) 0.81
Quantitative solubilization and analysis of insoluble paired helical filaments from Alzheimer disease. Brain Res (1996) 0.81
Heme oxygenase-1 induction in the brain during lipopolysaccharide-induced acute inflammation. Neuropsychiatr Dis Treat (2008) 0.81
The (un)balance between metabolic and oxidative abnormalities and cellular compensatory responses in Alzheimer disease. Mech Ageing Dev (2006) 0.80
Advanced glycation endproducts cause lipid peroxidation in the human neuronal cell line SH-SY5Y. J Alzheimers Dis (2003) 0.78
The protective role of DL-alpha-lipoic acid in biogenic amines catabolism triggered by Abeta amyloid vaccination in mice. Brain Res Bull (2005) 0.77
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Comparative genome sequencing of Drosophila pseudoobscura: chromosomal, gene, and cis-element evolution. Genome Res (2005) 8.38
Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci (2009) 3.77
Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A (2008) 3.68
AMPK is essential for energy homeostasis regulation and glucose sensing by POMC and AgRP neurons. J Clin Invest (2007) 3.32
The role of insulin receptor substrate 2 in hypothalamic and beta cell function. J Clin Invest (2005) 2.40
Oxidative stress and neurotoxicity. Chem Res Toxicol (2007) 2.12
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
Most reported genetic associations with general intelligence are probably false positives. Psychol Sci (2012) 2.10
Neural circuit involved in idiopathic infantile nystagmus syndrome based on FMRI. J Pediatr Ophthalmol Strabismus (2011) 2.02
Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. Brain Res Brain Res Rev (2003) 1.97
Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol (2006) 1.92
Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry (2003) 1.89
Overexpression of the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) in skeletal muscle repatterns energy metabolism in the mouse. J Biol Chem (2007) 1.85
Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis (2002) 1.85
Alzheimer's disease: the two-hit hypothesis. Lancet Neurol (2004) 1.81
Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog Neurobiol (2011) 1.80
A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry (2012) 1.76
Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35). Exp Neurol (2009) 1.75
The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Neurochem (2009) 1.67
Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol (2010) 1.66
Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta (2009) 1.66
The Promises and Pitfalls of Genoeconomics* Annu Rev Econom (2012) 1.66
Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol (2003) 1.66
Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem (2002) 1.65
Alzheimer disease. Dis Mon (2010) 1.64
Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem (2005) 1.61
Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem (2007) 1.61
Dominant role of the p110beta isoform of PI3K over p110alpha in energy homeostasis regulation by POMC and AgRP neurons. Cell Metab (2009) 1.59
Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J Neurochem (2011) 1.57
LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet (2012) 1.56
The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals (2003) 1.56
Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta (2006) 1.56
A new model of oxidative stress in rat pups. Neonatology (2008) 1.55
Impaired regulation of synaptic strength in hippocampal neurons from GluR1-deficient mice. J Physiol (2003) 1.55
Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. PLoS One (2010) 1.54
Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis (2010) 1.54
Chitin-like polysaccharides in Alzheimer's disease brains. Curr Alzheimer Res (2005) 1.51
Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta (2009) 1.49
Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann N Y Acad Sci (2004) 1.49
Pet-1 is required across different stages of life to regulate serotonergic function. Nat Neurosci (2010) 1.48
Cell cycle proteins in Alzheimer's disease: plenty of wheels but no cycle. J Alzheimers Dis (2002) 1.47
Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J (2002) 1.47
Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci U S A (2003) 1.46
4-Oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal. Chem Res Toxicol (2005) 1.46
Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology (2010) 1.46
Nucleic acid oxidation in Alzheimer disease. Free Radic Biol Med (2008) 1.45
Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol (2008) 1.45
Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J Nucl Med (2002) 1.44
The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J Neurochem (2009) 1.43
Leptin: a novel therapeutic strategy for Alzheimer's disease. J Alzheimers Dis (2009) 1.42
The end of a Chilean institute. Science (2005) 1.39
Temporal difference modeling of the blood-oxygen level dependent response during aversive conditioning in humans: effects of dopaminergic modulation. Biol Psychiatry (2007) 1.39
Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death. Hum Mol Genet (2011) 1.38
Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage. Invest Ophthalmol Vis Sci (2007) 1.37
Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res (2002) 1.37
Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis (2010) 1.37
Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis (2002) 1.34
Acute social defeat reduces neurotrophin expression in brain cortical and subcortical areas in mice. Brain Res (2004) 1.34
Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic Biol Med (2002) 1.34
Oxidative stress signalling in Alzheimer's disease. Brain Res (2004) 1.33